Pharming Group NV (PHAR) - Total Assets
Based on the latest financial reports, Pharming Group NV (PHAR) holds total assets worth $489.37 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Pharming Group NV - Total Assets Trend (2005–2025)
This chart illustrates how Pharming Group NV's total assets have evolved over time, based on quarterly financial data. Also see PHAR market cap for the company's overall valuation and market capitalisation.
Pharming Group NV - Asset Composition Analysis
Current Asset Composition (December 2025)
Pharming Group NV's total assets of $489.37 Million consist of 59.9% current assets and 40.1% non-current assets. Review PHAR total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 29.2% |
| Accounts Receivable | $54.69 Million | 10.9% |
| Inventory | $64.88 Million | 13.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $132.22 Million | 26.5% |
| Goodwill | $135.50 Million | 27.1% |
Asset Composition Trend (2005–2025)
This chart illustrates how Pharming Group NV's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Pharming Group NV for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pharming Group NV's current assets represent 59.9% of total assets in 2025, a decrease from 73.8% in 2005.
- Cash Position: Cash and equivalents constituted 29.2% of total assets in 2025, down from 42.5% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 53.0% of total assets, an increase from 11.0% in 2005.
- Asset Diversification: The largest asset category is goodwill at 27.1% of total assets.
Pharming Group NV Competitors by Total Assets
Key competitors of Pharming Group NV based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Pharming Group NV - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.63 | 2.76 | 5.25 |
| Quick Ratio | 2.06 | 2.00 | 4.74 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $183.16 Million | $136.57 Million | $170.90 Million |
Pharming Group NV - Advanced Valuation Insights
This section examines the relationship between Pharming Group NV's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.06 |
| Latest Market Cap to Assets Ratio | 1.52 |
| Asset Growth Rate (YoY) | 25.0% |
| Total Assets | $499.81 Million |
| Market Capitalization | $761.34 Million USD |
Valuation Analysis
Above Book Valuation: The market values Pharming Group NV's assets above their book value (1.52x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Pharming Group NV's assets grew by 25.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Pharming Group NV (2005–2025)
The table below shows the annual total assets of Pharming Group NV from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $499.81 Million | +24.96% |
| 2024-12-31 | $399.99 Million | -13.58% |
| 2023-12-31 | $462.85 Million | +8.70% |
| 2022-12-31 | $425.80 Million | +7.17% |
| 2021-12-31 | $397.31 Million | +15.99% |
| 2020-12-31 | $342.55 Million | +33.85% |
| 2019-12-31 | $255.91 Million | +4.27% |
| 2018-12-31 | $245.45 Million | +23.11% |
| 2017-12-31 | $199.38 Million | +49.53% |
| 2016-12-31 | $133.34 Million | +111.45% |
| 2015-12-31 | $63.06 Million | -6.93% |
| 2014-12-31 | $67.75 Million | +56.22% |
| 2013-12-31 | $43.37 Million | +94.69% |
| 2012-12-31 | $22.28 Million | -30.40% |
| 2011-12-31 | $32.01 Million | -35.46% |
| 2010-12-31 | $49.59 Million | -38.06% |
| 2009-12-31 | $80.07 Million | -14.28% |
| 2008-12-31 | $93.40 Million | -43.98% |
| 2007-12-31 | $166.72 Million | +59.74% |
| 2006-12-31 | $104.37 Million | +154.78% |
| 2005-12-31 | $40.96 Million | -- |
About Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more